Sutro Biopharma Inc (NAS:STRO)
$ 4.26 0.07 (1.67%) Market Cap: 348.44 Mil Enterprise Value: 56.75 Mil PE Ratio: 0 PB Ratio: 2.71 GF Score: 59/100

Sutro Biopharma Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 04:35PM GMT
Release Date Price: $7.34 (+2.66%)
Unidentified Analyst

All right. Good afternoon from the 31st Annual Credit Suisse Healthcare Conference. My name is [Jeffrey Weiner] from the U.S. Biotech team. It's my pleasure to introduce Sutro Biopharma and CEO, Bill Newell. After the presentation, we'll go into a short Q&A session if time allows. So thank you for joining us today.

And with that, you have the floor.

William J. Newell
Sutro Biopharma, Inc. - CEO & Director

Thank you, Jeff, and thank you, Credit Suisse for having us here today. And it's my pleasure to be presenting Sutro Biopharma to you. In the course of my presentation today, I will be making some forward-looking statements. This slide tells you everything you need to know about the qualifications behind those forward-looking statements. For those of you who are unfamiliar with Sutro Biopharma, let me give you a broad overview. We have the world's only platform that produces large molecules in a cell-free protein synthesis manner. This is sometimes known as in Vitro Transcription and Translation. The basic principles behind this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot